Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Dennis L Vargo"'
Autor:
Mark J Sarnak, Rajiv Agarwal, Neil Boudville, Pradip C P Chowdhury, Kai-Uwe Eckardt, Carlos R Gonzalez, Laura A Kooienga, Mark J Koury, Kwabena A Ntoso, Wenli Luo, Patrick S Parfrey, Dennis L Vargo, Wolfgang C Winkelmayer, Zhiqun Zhang, Glenn M Chertow
Publikováno v:
Nephrology Dialysis Transplantation.
Background Hypoxia-inducible factor prolyl hydroxylase inhibitors such as vadadustat may provide an oral alternative to injectable erythropoiesis-stimulating agents for treating anemia in patients receiving peritoneal dialysis. In two randomized (1:1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8d8766965288ed9f60a282b221f8f1c
https://doi.org/10.1093/ndt/gfad074
https://doi.org/10.1093/ndt/gfad074
Autor:
Rajiv Agarwal, Sanjeev Anand, Kai-Uwe Eckardt, Wenli Luo, Patrick S. Parfrey, Mark J. Sarnak, Christine M. Solinsky, Dennis L. Vargo, Wolfgang C. Winkelmayer, Glenn M. Chertow
Publikováno v:
American Journal of Nephrology. 53:701-710
Introduction: Anemia frequently occurs in chronic kidney disease (CKD), is associated with poor quality of life and cardiovascular outcomes, and its treatment represents a considerable economic burden to the healthcare system. Although effective, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ae1f880da6d02e2bd5d17d73f397c79
https://doi.org/10.1159/000528443
https://doi.org/10.1159/000528443
Autor:
Mark J. Koury, Rajiv Agarwal, Glenn M. Chertow, Kai‐Uwe Eckardt, Steven Fishbane, Tomas Ganz, Volker H. Haase, Mark R. Hanudel, Patrick S. Parfrey, Pablo E. Pergola, Prabir Roy‐Chaudhury, James A. Tumlin, Robert Anders, Youssef M. K. Farag, Wenli Luo, Todd Minga, Christine Solinsky, Dennis L. Vargo, Wolfgang C. Winkelmayer
Patients with chronic kidney disease (CKD) develop anemia largely because of inappropriately low erythropoietin (EPO) production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open-label, clinical trials in dial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95fbda48105c9cc626a3af0a7bab6c62
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-479451
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-479451
Autor:
Jeffrey R. Infante, Manpreet Chadha, Lindsey Wilson, Kathleen N. Moore, Dennis L. Vargo, Monette M. Cotreau, Andrew Strahs
Publikováno v:
Clinical Pharmacology in Drug Development. 3:284-289
Tivozanib hydrochloride (tivozanib) is a potent, selective tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors, with a long half-life. Tivozanib's effects on the QTc interval in patients with advanced solid tumors were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e508651cb0b10f0971ec40c18595efd
https://doi.org/10.1002/cpdd.113
https://doi.org/10.1002/cpdd.113
Publikováno v:
Clinical Pharmacology in Drug Development. 3:158-162
Tivozanib hydrochloride (tivozanib) is a potent, selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1, 2, and 3, with a long half-life. This Phase I study evaluated the effect of food on tivozanib pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4ace04e2d5e962483c99f9eba0d3997
https://doi.org/10.1002/cpdd.76
https://doi.org/10.1002/cpdd.76
Autor:
Madhu Sanga, Claudine S. Oelke, Strahs Andrew, Monette M. Cotreau, William Slichenmyer, Lindsey Jacobson, Christine Hale, Dennis L. Vargo, Robert G. Kochan
Publikováno v:
Clinical pharmacology in drug development. 1(3)
Objective To evaluate the absorption, metabolism, and excretion of tivozanib, a new investigational drug for renal cell carcinoma and solid malignancies. Methods Eight healthy male participants received a single 1.5-mg (˜160 μCi) dose of oral [(14)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11cf6a8d00cb3cba86609fd92d002aec
https://pubmed.ncbi.nlm.nih.gov/27121337
https://pubmed.ncbi.nlm.nih.gov/27121337
Autor:
Min H. Song, A. Benjamin Suttle, Jeff D. Fischer, Charles B. Burns, Dennis L. Vargo, William D. Heizer, Kim L. R. Brouwer
Publikováno v:
Pharmaceutical Research. 17:154-159
Purpose. This study characterized the gastrointestinal (GI) absorptionof zafirlukast after oral and colonic administration in humans.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a36ec7164e0ba78639ce4be49aca8988
https://doi.org/10.1023/a:1007509112383
https://doi.org/10.1023/a:1007509112383
Autor:
Kathleen, Moore, Jeffrey R, Infante, Monette M, Cotreau, Lindsey, Wilson, Andrew L, Strahs, Dennis L, Vargo, Manpreet, Chadha
Publikováno v:
Clinical pharmacology in drug development. 3(4)
Tivozanib hydrochloride (tivozanib) is a potent, selective tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors, with a long half-life. Tivozanib's effects on the QTc interval in patients with advanced solid tumors were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3bf6a44c57acb6b7eb305d31e56672f6
https://pubmed.ncbi.nlm.nih.gov/27128834
https://pubmed.ncbi.nlm.nih.gov/27128834
Autor:
Monette M, Cotreau, Lisa, Massmanian, Andrew L, Strahs, William, Slichenmyer, Dennis L, Vargo
Publikováno v:
Clinical pharmacology in drug development. 3(2)
Tivozanib hydrochloride (tivozanib) is a potent, selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1, 2, and 3, with a long half-life. This Phase I study evaluated the effect of food on tivozanib pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::30def528ff5f2b5dd0df4c669bf55f0b
https://pubmed.ncbi.nlm.nih.gov/27128461
https://pubmed.ncbi.nlm.nih.gov/27128461
Autor:
D. Craig Brater, William B. Smith, Dennis L. Vargo, Tina Serpas, William G. Kramer, Paula K. Black
Publikováno v:
Clinical Pharmacology & Therapeutics. 57:601-609
The bioavailability, pharmacokinetics, and pharmacodynamics of torsemide (10 mg orally and intravenously) and furosemide (40 mg orally and 20 mg intravenously) were determined in a randomized crossover clinical trial in 16 patients with compensated c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9bb4628d58920506a92f992862d953b
https://doi.org/10.1016/0009-9236(95)90222-8
https://doi.org/10.1016/0009-9236(95)90222-8